Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1 (BEST-IgAN-1)
A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients
Sponsor: Ajou University School of Medicine
Listed as NCT03357653, this PHASE3 trial focuses on Glomerulonephritis, Immunoglobulin A (IgA) and remains ongoing. Sponsored by Ajou University School of Medicine, it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Feb 2020 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ajou University School of Medicine
- Chonbuk National University Hospital
- Chonnam National University Hospital
- Eulji General Hospital
- Ewha Womans University
- Gangnam Severance Hospital
- Hallym University Medical Center
- Kangdong Sacred Heart Hospital
- Korea University Guro Hospital
- Kyung Hee University Hospital at Gangdong
- Kyungpook National University Hospital
- National Health Insurance Service Ilsan Hospital
- Pusan National University Yangsan Hospital
- SMG-SNU Boramae Medical Center
- Seoul National University Bundang Hospital
- Seoul National University Hospital
- Severance Hospital
- The Catholic University of Korea
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.